ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and rituximab"

  • Abstract Number: 931 • 2019 ACR/ARP Annual Meeting

    Ultra-Low Doses of Rituximab for Retreatment of RA: A Randomized Controlled Non-Inferiority Trial

    Lise Verhoef1, Nathan den Broeder 1, Rogier Thurlings 2, Willemijn van der Laan 1, Wilfred van der Weele 3, Marc Kok 4, Hein Bernelot Moens 5, Thasia Woodworth 6, Bart van den Bemt 1, Frank van den Hoogen 1 and Alfons den Broeder 1, 1Sint Maartenskliniek, Nijmegen, Netherlands, 2Radboudumc, Nijmegen, Netherlands, 3Reade, Amsterdam, Netherlands, 4Maasstad Hospital, Rotterdam, Netherlands, 5Ziekenhuisgroep Twente, Almelo, Netherlands, 6University of California, Los Angeles, CA

    Background/Purpose: Rituximab is an effective treatment for patients with RA. 1000mg (1×1000mg or 2×500mg) has similar six-month efficacy as the registered dose of 2×1000mg.(1) Based…
  • Abstract Number: 147 • 2018 ACR/ARHP Annual Meeting

    T Follicular Helper Cell Phenotype in RA Patients Receiving Rituximab

    Betty Hsiao1, Jin-Young Choi2 and Joseph E. Craft3, 1Yale University School of Medicine, New Haven, CT, 2Section of Rheumatology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, 3Department of Internal Medicine/Rheumatology, Yale University School of Medicine, New Haven, CT

    Background/Purpose: B and T cells contribute to tissue injury in rheumatoid arthritis (RA). Rituximab (RTX), an anti-CD20 monoclonal antibody, is used for the treatment of…
  • Abstract Number: 521 • 2018 ACR/ARHP Annual Meeting

    The Lung in an English Cohort of Rheumatoid Arthritis Patients – an Overview of Different Types of Involvement and Treatment

    Ana Catarina Duarte1, Maria José Leandro2 and Joanna Porter3, 1Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, 2Center for Rheumatology, University College London, London, United Kingdom, London, United Kingdom, 3Department of Respiratory Medicine, University College London, London, United Kingdom, London, United Kingdom

    Background/Purpose: Lung disease is described in 5–20% of pts (pts) with RA and affects parenchyma, pleura, airways and vasculature; drug-induced pulmonary disease also occurs. It…
  • Abstract Number: 617 • 2018 ACR/ARHP Annual Meeting

    Long-Term Outcome of Rituximab in Rheumatoid Arthritis: Real World Experience

    Candice Low1, Richard Conway1, Francis Young2, Eamonn S. Molloy3, Anne Barbara Mongey3, Oliver FitzGerald4, Anthony G. Wilson5, Ursula Fearon6 and Douglas J. Veale1, 1Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland, 2Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin 4, Ireland, 3Saint Vincent's University Hospital, Dublin 4, Ireland, 4Department of Rheumatology, St Vincent's University Hospital and Conway Institute, University College Dublin, Ireland, Dublin, Ireland, 5UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland, 6Molecular Rheumatology, School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland

    Background/Purpose: Rituximab is an effective treatment for rheumatoid arthritis (RA). Data on long-term outcomes following rituximab treatment are limited. The aim of this study was…
  • Abstract Number: 1500 • 2018 ACR/ARHP Annual Meeting

    The Multi-Biomarker Disease Activity Score Tracks Response to Rituximab Treatment in Rheumatoid Arthritis Patients

    Nadia MT Roodenrijs1, Maria JH de Hair1, Gill Wheater2, Mohsen Elshahaly3, Janneke Tekstra1, Y.K. Onno Teng4, Floris PJG Lafeber1, Ching Chang Hwang5, Xinyu Liu6, Eric H. Sasso5 and Jacob van Laar1, 1Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, 2Department of Biochemistry, The James Cook University Hospital, Middlesbrough, UK, Middlesbrough, United Kingdom, 3Department of Rheumatology & Rehabilitation, Suez Canal University, Ismailia, Egypt, Ismailia, Egypt, 4Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands, 5Crescendo Bioscience, San Francisco, CA, USA, South San Francisco, CA, 6Crescendo Bioscience, San Francisco, CA, USA, San Francisco, CA

    Background/Purpose: A multi-biomarker disease activity (MBDA) score was developed to objectively measure disease activity for patients with rheumatoid arthritis (RA).1 The MBDA score is calculated…
  • Abstract Number: 2515 • 2018 ACR/ARHP Annual Meeting

    Joint Damage Progression According to Disease Activity States in Patients with Rheumatoid Arthritis Treated with CT-P10 and Reference Rituximab: Up to 48 Weeks Results from Phase III Study

    Chang-Hee Suh1, Dae-Hyun Yoo2, Won Park3, Seung-Cheol Shim4, Sang-Joon Lee5, Yun Ju Bae5, Sang Eun Han5 and Sang Mi Lee5, 1Rheumatology, Ajou University School of Medicine, Suwon, Korea, Republic of (South), 2Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), 3Medicine/Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South), 4Division of Rheumatology, Department of Internal Medicine, Daejeon Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Daejeon, Korea, Republic of (South), 5CELLTRION, Inc., Incheon, Korea, Republic of (South)

    Background/Purpose: CT-P10 is a biosimilar of the reference rituximab (RTX) and has been approved by several regulatory agencies including EMA. Pharmacokinetic and therapeutic equivalence from…
  • Abstract Number: 2825 • 2018 ACR/ARHP Annual Meeting

    Reduction of Antidrug Antibody Levels after Switching to Rituximab in Patients with Rheumatoid Arthritis with Previous Failure to Infliximab or Adalimumab

    Ana Martínez1,2, Chamaida Plasencia2,3, Victoria Navarro-Compán2, Borja Hernández-Breijo2, Dora Pascual-Salcedo2, Pilar Nozal4, Cristina Diego4, Irene Monjo2,3, Laura Nuño3,5 and Alejandro Balsa2,6, 1Immunology. La Paz University Hospital, Madrid, Spain, 2Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain, 3Rheumatology, La Paz University Hospital, Madrid, Spain, 4La Paz University Hospital, Immunology, Madrid, Spain, 5Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, madrid, Spain, 6Hospital Universitario La Paz, Madrid, Spain

    Background/Purpose: Rituximab (Rtx) induces transient depletion of B cells. Previous data showed that Rtx is particularly effective on autoimmune diseases in which auto-antibodies (auto-Ab) are…
  • Abstract Number: 496 • 2017 ACR/ARHP Annual Meeting

    Repeated Rituximab Infusions for the Therapy of Rheumatoid Arthritis Is Not Associated with Increased Rates of Serious Infections

    Dimitrios A. Pappas1,2, George W. Reed1,3, Steve Zlotnick4, Jennie Best4, Robert Magner3, Gioia Persuitte1 and Jeffrey D Greenberg1,5, 1Corrona, LLC, Southborough, MA, 2Department of Medicine, Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, 3University of Massachusetts Medical School, Worcester, MA, 4Genentech, Inc., South San Francisco, CA, 5NYU School of Medicine, New York, NY

    Background/Purpose: Extended observations in clinical trials have not demonstrated an increased risk of serious infection events (SIE) in patients with rheumatoid arthritis (RA) treated with…
  • Abstract Number: 1346 • 2017 ACR/ARHP Annual Meeting

    Selective Effect of Rituximab on IgG4 Anti-CCP Autoantibodies in Rheumatoid Arthritis Patients

    Mercedes Rincon1,2, Sarah Kelso3, Janice Bunn4 and Sheldon Cooper5, 1Department of Medicine/Rheumatology, University of Vermont, Burlingont VT, VT, 2Department of Medicine/Immunobiology, University of Vermont, Burlington, VT, 3Department of Medicine/Rheumatology, Univeristy of Vermont, Burlington, VT, 4Mathematics and Statistics, University of Vermont, Burlington, VT, 5Department of Medicine/Rheumatology, University of Vermont, Burlington, VT

    Background/Purpose: Autoantibodies have long been recognized to be present in patients with RA, but it is more recent that autoantibodies against citrullinated proteins (anti-CCP) are…
  • Abstract Number: 1466 • 2017 ACR/ARHP Annual Meeting

    The Effects of Rituximab and B-Cells Depletion on the Inflammatory and Pro-Thrombotic Profile of Leucocytes of Rheumatoid Arthritis Patients and on the Vascular Endothelium

    Irene Cecchi1, Carlos Perez-Sanchez2, Patricia Ruiz-Limon3, Ivan Arias de la Rosa3, Maria Carmen Abalos-Aguilera3, Yolanda Jiménez-Gómez2, Rafaela Ortega-Castro2, Eduardo Collantes-Estévez2, Alejandro Escudero-Contreras3, Massimo Radin4, Nuria Barbarroja2, Dario Roccatello5, Savino Sciascia6 and Chary Lopez-Pedrera7, 1Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, 2Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 3Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 4Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, 5Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, 6Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, 7IMIBIC/Reina Sofia Hospital/ University of Cordoba, Cordoba, Spain

    Background/Purpose: Cardiovascular disease (CVD) constitutes a relevant cause of morbidity and mortality in Rheumatoid Arthritis (RA) patients. Rituximab (RTX) has been proved to be effective…
  • Abstract Number: 1472 • 2017 ACR/ARHP Annual Meeting

    Body Mass Index Does Not Affect Response to Rituximab in Patients with Rheumatoid Arthritis: Results from Turkbio Registry

    Suleyman Serdar Koca1, Ahmet Karatas2, Burak Oz3, Ediz Dalkilic4, Gerçek Can5, Yavuz Pehlivan6, Ayten Yazici7, Nevsun Inanc8, Ayse Cefle9, Zeypen Erturk10, Servet Akar11, Soner Senel12, Merih Birlik13, Nurullah Akkoc14 and Fatos Onen15, 1Department of Rheumatology, Firat University School of Medicine, Elazig, Turkey, 2Department of Rheumatology, Firat University, School of Medicine, Rheumatology, Elazig, Turkey, 3Rheumatology, Firat University, School of Medicine, Rheumatology, Elazig, Turkey, 4Department of Internal Medicine, Division of Rheumatology, Uludag University, School of Medicine, Rheumatology, Bursa, Turkey, 5Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, 6Department of Rheumatology, Uludag University, Bursa, Turkey, 7Rheumatology, Kocaeli University, Kocaeli, Turkey, 8Departement of İnternal Medicine, Division of Rheumatology, Marmara University, Istanbul, Turkey, 9Rheumatology, Kocaeli University, School of Medicine, Rheumatology, Kocaeli, Turkey, 10Department of Rheumatology, Marmara Univeristy School of Medicine, Istanbul, Turkey, 11Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, 12Rheumatology, Kayseri Erciyes University, School of Medicine, Rheumatology, Kayseri, Turkey, 13Department of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, 14Rheumatology, Private Practice, Rheumatology, İzmir, Turkey, 15Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey

    Background/Purpose: Adipose tissue produces several inflammatory mediators. Thus, obesity affects the disease course and the responses to the anti-rheumatic agents in inflammatory diseases. Several previous…
  • Abstract Number: 2385 • 2017 ACR/ARHP Annual Meeting

    High Incidence of Hepatitis Related to HBV Reactivation in Rheumatoid Arthritis Patients with Resolved Hepatitis B Infection during Rituximab Treatment

    Ming-Han Chen1, Yen-Po Tsao2, Yi-Hsiang Huang3, Chung-Tei Chou4 and Chang Youh Tsai2, 1Division of Allergy- Immunology- Rheumatology, Department of Medicine, Division of Allergy- Immunology- Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, 2Division of Allergy- Immunology- Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, 3Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, 4Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan

    AbstractBackground/Purpose: Rituximab-based chemotherapy can induce hepatitis B virus (HBV) reactivation (HBVr) in patients with hematological malignancies who have been exposed to HBV infection. However, informative…
  • Abstract Number: 2402 • 2017 ACR/ARHP Annual Meeting

    Rituximab in Rheumatoid Arthritis with Interstitial Lung Disease: A Multicenter Study of 32 Patients

    Carlos Fernández-Díaz1, Delia Reina2, Paula Rubio-Muñoz3, Ana Urruticoechea-Arana4, María Carrasco-cubero5, María Martín-López6, Jose A. Miranda-Filloy7, Ignacio Villa-Blanco8, Ana Milena Millan9, Ivan Castellví10, Olga Maiz-Alonso11, Antonio Juan12, Fátima Álvarez Reyes13, José Luis Martín-Varillas1, Nuria Vegas-Revenga1, Ricardo Blanco1 and Miguel Angel González-Gay1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, 3Rheumatology,, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, 4Rheumatology Department. Hospital Can Misses, IBIZA, Spain, 5Hospital Infanta Cristina, Badajoz, Spain, 6Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, 7Rheumatology Division, Hospital Lucus Augusti, Lugo, Spain, 8Hospital de Sierrallana, Sierrallana, Spain, 9Unitat de Reumatologia. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 10Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, 11Hospital Universitario Donostia. San Sebastian. Spain, Donostia, Spain, 12Hospital Universitario Son Llàtzer. Rheumatology, Palma de Mallorca, Spain, 13Rheumatology, University Hospital Ntra. Sra. de La Candelaria, Santa Cruz de Tenerife, Spain

    Background/Purpose: Anti-TNFα drugs and several conventional disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate (MTX) have been involved in the development of Interstitial Lung Disease (ILD).…
  • Abstract Number: 2445 • 2017 ACR/ARHP Annual Meeting

    Efficacy and Safety of Rituximab Biosimilar, CT-P10, after a Single Switch from Innovator Rituximabs in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 72 Weeks

    Seung-Cheol Shim1, Ljubinka Bozic Majstorovic2, Alfredo Berrocal Kasay3, Elias Chalouhi El-Khouri4, Fedra Irazoque-Palazuelos5, Francisco Cons Molina6, Francisco G. Medina-Rodriguez7, Pedro Miranda8, Pavel Shesternya9, Jose Chavez Corrales10, Piotr Wiland11, Slawomir Jeka12, Olena Garmish13, Pawel Hrycaj14, Natalia Fomina15, Won Park16, Chang-Hee Suh17, Sang-Joon Lee18, Sung Young Lee19 and Dae-Hyun Yoo20, 1Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea, Republic of (South), 2Clinical Centre Banja Luka, Bonja Luka, Bosnia and Herzegovina, 3ABK Reuma SRL – Medicentro Biociencias, Lima, Peru, 4Clinica Internacional, Lima, Peru, 5Centro de Invstigacion y Tratamiento Reumatologico S.C, Mexico City, Mexico, 6Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, 7Rheumatology, LaSalle University, Mexico City, Mexico, 8Centro De Estudios Reumatológicos, Santiago, Chile, 9Rheumatology Department, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, 10Clinica San Borja, Lima, Peru, 11Department and Clinic of Rheumatology and Internal Medicine, Medical University, Wroclaw, Poland, 122nd University Hospital, CM UMK, Department of Rheumatology and Connective Tissue Diseases,, Bydgoszcz, Poland, 13Institute of Cardiology named by M.D. Strazhesko NAMS of Ukraine, Kyiv, Ukraine, 14Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland, 15Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation, 16Medicine/Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South), 17Ajou University School of Medicine, Suwon, Korea, Republic of (South), 18CELLTRION, Inc., Incheon, Korea, Republic of (South), 19Clinical Planning Department, CELLTRION, Inc., Incheon, Korea, Republic of (South), 20Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)

    Background/Purpose: Similarity of pharmacokinetic, efficacy and safety between CT-P10 and reference rituximab (RTX) were shown in the phase 3 randomized controlled trial (NCT02149121) up to…
  • Abstract Number: 2461 • 2017 ACR/ARHP Annual Meeting

    Rituximab Is Effective in the Treatment of Rheumatoid Arthritis Irrespective of Body Mass Index; Up to 48 Weeks Results from Phase 3 Study

    Dae-Hyun Yoo1, Won Park2, Chang-Hee Suh3, Seung-Cheol Shim4, Sang-Joon Lee5, Yun Ju Bae5, Chan Park5 and Noo Ri Han5, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), 2Medicine/Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South), 3Ajou University School of Medicine, Suwon, Korea, Republic of (South), 4Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea, Republic of (South), 5CELLTRION, Inc., Incheon, Korea, Republic of (South)

    Background/Purpose: High body mass index (BMI) is known to be associated with inadequate clinical response to anti-TNF agents in RA patients.1 However, there are limited…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology